NEJM Journal Watch Cardiology selected ISCHEMIA and ISCHEMIA-CKD as their 2020 Top Stories.
An excerpt from their announcement:
“Our top story is the same as last year's, the ISCHEMIA trial. Last year, we felt compelled to choose it, even as we awaited publication of the study. With its publication this year, we are again ranking it at the top. This trial is indeed game-changing, even as some people debate it around the edges. Its main finding was that an invasive strategy for patients with stable ischemic heart disease did not improve survival or reduce the risk for myocardial infarction (MI). We also have selected the substudy focusing on patients with chronic kidney disease, in whom the invasive strategy did not confer a benefit in clinical outcomes or health status.”